39 results about "Sarcoidosis" patented technology

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

Compositions and related methods are provided, the compositions comprising an anti-TNF alpha antibody sialylated with one or more N-acetylneuraminic acid molecules. In some embodiments, methods for treating or preventing sarcoidosis and / or granulomegaly or formation in a patient in need thereof are provided.

Described are methods for treating patients with pulmonary hypertension associated with sarcoidosis (PH-SARC) using inhaled nitric oxide (iNO).

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof. In some embodiments, an outcome of the methods of the present technology is increased relative to the same method comprising use of a corticosteroid.

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention pertains to the field of pharmacology and medicine, specifically to the use of the IL-6 inhibitor olokizumab for the treatment of progressive fibrotic interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, lymphocytic interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, hypersensitivity pneumonitis (allergic alveolitis), sarcoidosis; interstitial pneumonia with autoimmune features; pneumoconioses; pulmonary histiocytosis; interstitial lung disease associated with autoimmune diseases, such as systemic sclerosis; rheumatoid arthritis; systemic lupus erythematosus; polymyositis / dermatomyositis; primary Sjögren's syndrome; mixed connective tissue disease; other systemic connective tissue diseases, as well as polymyalgia rheumatica and giant cell arteritis. This disclosure can be used for the effective therapy of progressive fibrotic ILDs, as polymyalgia rheumatica, and giant cell arteritis expanding the range of medications used to treat these conditions.

The present invention provides pharmaceutical compounds of formula I wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have the meanings given in the specification, which are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases such as idiopathic pulmonary fibrosis and sarcoidosis. # imgabs0 #

The invention belongs to the technical field of traditional Chinese medicines, and provides application of American cockroach powder in a medicine for treating pulmonary sarcoidosis. The invention provides a new application of periplaneta americana in medicine, the number of nodules of a pulmonary nodule mouse model can be remarkably reduced, and a new direction is provided for development of the traditional Chinese medicine periplaneta americana.

The disclosure provides a method of treating sarcoidosis, the method comprising administering a GHRH antagonist to mammalian subject in need thereof.

The invention belongs to the field of traditional Chinese pharmacology, and provides application of American cockroach powder in a medicine for treating thyroid sarcoidosis. The invention further provides a traditional Chinese medicine composition for treating pulmonary nodule. The traditional Chinese medicine composition is prepared from, by weight, 6-9 parts of American cockroach, 3-10 parts of radix bupleuri, 6-10 parts of rhizoma cyperi, 3-9 parts of rhizoma pinelliae preparata, 9-15 parts of selfheal and 5-10 parts of thunberg fritillary bulb. The invention provides a new application of the American cockroach powder in medicine, and clinically finds that the American cockroach powder has a good effect of treating thyroid nodules independently or together with other traditional Chinese medicines, so that a new direction is provided for the development of the traditional Chinese medicine American cockroach.

There is provided herein a compound of formula I,wherein R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 and R6 are as defined herein, which compounds are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

There is provided herein a compound of formula I, wherein R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 and R6 are as defined herein, which compounds are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

Sarcoidosis is a multisystem disease characterized by granulomatous inflammation in affected organs. The present invention discloses kits and a system for a blood test using mycobacterial catalase-peroxidase that has a high positive predictive value for confirming a diagnosis of sarcoidosis.

The pharmaceutical compound or the pharmaceutically acceptable salt thereof is used for preventing or treating the following diseases by simultaneously inhibiting autotaxin (ATX) and activating peroxisome proliferator-activated receptor gamma (PPAR gamma): a) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases, and b) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases; the present invention relates to a pharmaceutical composition for treating hepatitis, such as various hepatitis and / or non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and / or cirrhosis, where said ILD may be a primary disease, preferably idiopathic pulmonary fibrosis and / or sarcoidosis and / or interstitial pneumonia, or said ILD is a complication associated with an autoimmune and / or inflammatory and / or metabolic disease, or a pharmaceutical composition comprising said ILD. Preferably rheumatoid arthritis ILD and / or scleroderma ILD and / or myositis ILD and / or diabetes ILD and / or cardiovascular disease ILD; and / or b) inflammatory and / or autoimmune diseases, preferably rheumatoid arthritis and / or scleroderma; and / or c) cancer, in particular lung and / or hepatocellular carcinoma and / or pancreatic cancer and / or glioblastoma and / or neuroblastoma; and / or d) a metabolic disease, in particular diabetes mellitus type 1 and / or diabetes mellitus type 2 and / or obesity, having a formula selected from the group consisting of formulae (A), (B), (C), (D), (E), (F), (G) and (H).

The invention provides a traditional Chinese medicine composition for treating benign nodules and a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 12 to 18 parts of bistort rhizome, 24 to 36 parts of hairyvein agrimony, 9.6 to 14.4 parts of pseudobulbus cremastrae seu pleiones, 16 to 24 parts of fructus forsythiae, 12 to 18 parts of platycodon grandiflorum, 16 to 24 parts of thunberg fritillary bulb and 14.4 to 21.6 parts of spanishneedles herb. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition aims at the core pathogenesis of qi stagnation and blood stasis syndromes of sarcoidosis, namely phlegm and blood stasis, and heat from depression to qi, has the effects of clearing heat, eliminating stagnation, reducing phlegm, removing blood stasis, tonifying qi and strengthening the body resistance, is used for treating benign nodules of lung, thyroid or mammary gland, achieves the effect of treating different diseases at the same time, and has the advantages of being definite in curative effect, small in side effect and capable of preventing relapse.

The invention discloses a preparation method of a medicinal and edible compound composition for treating sarcoidosis, and relates to the technical field of medicines and foods. The method comprises the following steps: A, carrying out low-temperature superfine grinding, namely respectively and accurately weighing the raw materials of red tangerine peel, perilla frutescens and semen brassicae, putting into a superfine grinding machine in a liquid nitrogen environment at the temperature of 40 DEG C below zero, and grinding for 30 minutes; through low-temperature superfine grinding and sectional cold extraction, volatile and heat-sensitive components of raw materials such as exocarpium citri rubrum and brassica juncea are protected, various effective components such as flavonoid glycoside and total flavonoids are completely reserved, anti-cancer components are activated through targeted enzymolysis, the drug effect is enhanced through hot-phase transduction concentration, the mucous membrane adhesion microsphere and nano-composite technology is combined, and the anti-cancer effect is achieved. The compound prepared from the medicinal and edible raw materials can be used for medicines, health care products and functional foods, provides choices for treatment, prevention and adjuvant treatment of sarcoidosis, is high in safety, and is suitable for long-term use.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The application provides a traditional Chinese medicine composition for treating benign nodules and a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from raw medicinal materials in the following weight ratio: Bistorta 12-18 parts, Agrimonia pilosa 24-36 parts, Laetiporus 9.6-14.4 parts, Forsythia 16-24 parts, Platycodon 12-18 parts, Fritillaria thunbergii Miq. 16-24 parts and Begonia fimbristipula 14.4-21.6 parts. The application also provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition aims at the core pathogenesis of phlegm and blood stasis syndrome of tuberculosic disease, has the effects of clearing heat, resolving nodules, resolving phlegm and removing blood stasis, and has the effects of tonifying qi and supporting healthy energy, is used for treating benign nodules of the lung, thyroid or breast, achieves the effect of treating different diseases in the same way, and has the advantages of accurate curative effect, small side effect and prevention of recurrence.

At present, the treatment methods for sarcoidosis include operative treatment, radiochemical treatment and drug treatment (including traditional Chinese medicine decoction). Wherein the operative treatment has a good curative effect on early-stage patients, but the treatment cost is high; the treatment effect on advanced patients is poor; traditional Chinese medicine decoction is long in conditioning time and slow in treatment speed. In order to better treat nodule diseases and overcome the defects in the prior art, the invention provides the liqueur for treating nodules, which can effectively treat various nodules, and has the advantages of simultaneous treatment of medicine and food, small side effect, low cost and good curative effect.

Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The disclosure provides a method of treating sarcoidosis, the method comprising administering a GHRH antagonist to mammalian subject in need thereof.

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof.

The disclosure relates to a sarcoidosis animal model and methods of inducing sarcoidosis in an animal. The disclosure also relates to methods of producing an in vitro granuloma, and methods of using the sarcoidosis animal model. Disclosed herein are animals comprising one or more granulomas, wherein the one or more granulomas comprise Mycobacterium abscessus cell wall microparticles.

Provided herein are methods for the detection and treatment of sarcoidosis, and more particularly, to method to determine whether a subject with have a low or high sarcoidosis disease burden by applying an algorithm to the measured protein expression, wherein the algorithm compares the measured protein expression levels to a reference level of a subject without sarcoidosis, wherein the algorithm is selected from a machine learning algorithm, a clustering algorithm, a support vector machine, or combinations thereof. A treatment is selected based on the comparison predicting if the subject has sarcoidosis that will resolve without treatment (low sarcoidosis disease burden), of if the sarcoidosis will lead to severe sarcoidosis (high sarcoidosis disease burden).

The present invention relates to (i) S-pindolol; and (ii) a pharmaceutically acceptable acid addition salt of an organic acid, wherein the organic acid has a pKa1 of 2.5 or higher; and the chemical formula CxHy(CO2H)z, where x is 1 to 10, y is 2 to 20, and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful for treating conditions such as cachexia, sarcoidosis, neuromuscular disorders, and muscle weakness.

The invention relates to the technical field of medical instruments, in particular to a thyroid nodule pathology precise sampling system which comprises a receiving module used for receiving tissue lesion types, positions, colors and shape features of past postoperative pathology sampling; the data processing module is used for constructing association between tissue lesion types and position, color and shape features, and constructing a judgment model in combination with a basic principle of pathological sampling; the guidance module is used for acquiring a three-dimensional image of the sample, generating a guidance scheme according to the three-dimensional image and the judgment model, and projecting guidance light to the sample according to the guidance scheme; the correction module is used for judging the position of the scalpel according to the breakpoint position of the guiding light on the sample, judging whether the scalpel moves along the guiding light or not according to the position of the scalpel, and giving an alarm to a user only when the scalpel does not move along the guiding light.

Provided herein are compositions and methods for treating neuroinflammatory diseases and conditions, the neuroinflammatory diseases and conditions include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), optic neuromyelitis (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), vascular dementia (VAD), anti-oligodendroglia glycoprotein antibody disease (MOGAD), and the like. Transverse myelitis (TM), autoimmune encephalitis (AE), acute disseminated encephalomyelitis (ADEM), chronic meningitis (CM), central nervous system (CNS) vasculitis, hashimoto encephalitis (HE), neurosarcoidosis (NS), multi-system atrophy (MSA), migraine, chemotherapy-induced pain or dementia-related pain.

The present invention relates to a pharmaceutical compound or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of the following conditions, wherein the pharmaceutical compound or a pharmaceutically acceptable salt thereof is characterized in that it simultaneously inhibits autotaxin (ATX) and agonizes PPARγ, and has a chemical formula selected from the group consisting of formulas (A), (B), (C), (D), (E), (F), (G), and (H): a) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases such as all types of hepatitis and / or non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and / or cirrhosis, where the ILD is a primary disease, preferably idiopathic pulmonary fibrosis and / or sarcoidosis and / or interstitial pneumonia, or where the ILD is associated with an autoimmune and / or inflammatory and / or metabolic disease, preferably rheumatoid arthritis-ILD ​​and / or scleroderma-ILD and / or myositis-ILD ​​and / or diabetes-ILD ​​and / or cardiovascular disease-ILD combination, and / or b) an inflammatory and / or autoimmune disease, preferably rheumatoid arthritis and / or scleroderma, and / or c) cancer, in particular lung cancer and / or hepatocellular carcinoma and / or pancreatic cancer and / or glioblastoma and / or neuroblastoma, and / or d) metabolic diseases, in particular type 1 diabetes and / or type 2 diabetes and / or obesity [Formula 1] TIFF2026503883000014.tif94126